Positive Clinical Experience Observed Underscores Unmatched Benefit MuGard Provides as Oral Mucositis Protection While Treating for Various Types of Cancers

Dallas, TX and New York, NY, February 9, 2011

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, reported it has been receiving positive clinical feedback from doctors and nurse practitioners prescribing MuGard for patients undergoing radiation and chemotherapy for various cancers.  For example, Access received feedback from a prescribing nurse practitioner at a leading southwest oncology practice. MuGard was introduced to the practice over three months ago and since then has been incorporated into the supportive care regimens of approximately 80 cancer patients, comprised of head and neck, lung, colon and breast cancer patients.

Throughout the prescriber’s feedback, provided to Access in a Q&A format, the nurse practitioner detailed many of the distinct benefits MuGard provided her patients, highlighting “…MuGard has worked on all but one patient…,” and adding “…MuGard has made a huge impact in our practice.  Our patients are thrilled….they are absolutely ecstatic.  It’s the first product for oral mucositis we’ve had to give them that has made a difference.”  The feedback also covers prior unsuccessful treatments used by the prescriber for oral mucositis before learning about MuGard. The detailed feedback can be viewed under the “testimonials” section of the MuGard website, www.MuGard.com, or by clicking on the following link, http://www.mugard.com/testimonials/.
Read more »